



RETHINKING THROMBIN IN HAEMOPHILIA

Wednesday, 3 February 2021
18:00–19:00 hrs (CET)

Despite recent advances in the treatment of people with haemophilia, **challenges and unmet needs remain**. Clinical research has demonstrated benefit from targeting natural anticoagulants to **rebalance and maintain effective haemostasis**. This symposium will aim to review the **importance of thrombin generation and antithrombin lowering sufficient to rebalance haemostasis** in people with haemophilia. We will also **examine novel therapeutic options** for people with haemophilia A or B, with or without inhibitors, designed to address those unmet needs and to rethink the optimised approach to haemophilia care.

18:00–18:05

Introduction

Professor K. John Pasi (Chair, UK)

18:05–18:15

The central role of thrombin generation in haemostasis

Professor Maureane R. Hoffman (USA)

18:15–18:25

Role of antithrombin (AT) regulation in haemostasis

Professor Maureane R. Hoffman (USA)

18:25–18:35

Challenges and unmet needs in the treatment of people with haemophilia

Professor K. John Pasi (Chair, UK)

18:35–18:50

Safety and efficacy of fitusiran for the treatment of people with haemophilia: Phase II data

Professor Margaret V. Ragni (USA)

18:50–19:00

Panel discussion

All faculty

SANOFI GENZYME 

